Off-brand weight-loss drug makers are suing the FDA, again
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another lawsuit against...
Bruce Gil
The Ozempic shortage is over
The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S. Food and...
Ozempic, Eliquis, Keytruda: The 9 top-selling drugs of 2024
Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these...
Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup
Graphic: Images: Hims & Hers, Bloomberg / Contributor, Steve Christo - Corbis / Contributor, UCG / ContributorSales of Eli Lilly’s...
The Ozempic boom is slowing down
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy doubled in the fourth quarter, but the Danish pharmaceutical giant warns...
Big Pharma has a big Super Bowl dilemma
Big Pharma often turns to NFL games to hawk their blockbuster treatments, but drug makers have typically been hesitant to...
The FDA just approved Ozempic for kidney disease
Novo Nordisk (NVO) announced today that its blockbuster drug Ozempic was approved by the Food and Drug Administration (FDA) as...
